Comparison · NCT02800785-010a942b
Antibiotics Therapy Arm vs Appendectomy Arm: Rates of Participants With Appendiceal Cancer
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Antibiotics Therapy Arm vs Appendectomy Arm: Rates of Participants With Appendiceal Cancer. Trial comparisons, record NCT02800785-010a942b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02800785-010a942b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00515 | 0.00201 | 0.0132 | wilson | |
| Risk in group 2 | 0.00773 | 0.00355 | 0.0168 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00258 | -0.0121 | 0.00647 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.667 | 0.189 | 2.35 | log | |
| Odds ratio, group 1 over group 2 | 0.665 | 0.187 | 2.37 | log | |
| Number needed to treat, for one fewer participant with the outcome on Antibiotics Therapy Arm than on Appendectomy Arm | 388 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Antibiotics Therapy Arm | Patients in the antibiotics (abx) arm will receive a total of 10 days of abx, with a minimum of 24 hours using an IV abx formulation (administered in q8, q12, or q24 hour regimens with or without concurrent oral abx) followed by oral abx for the remainder of the 10 days. Patients will be offered a treatment regimen of abx based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. Any of the IV abx options (Single antibiotic-Cefoxitin, Ertapenem, Moxifloxicin, Tigecycline, Ticarcillin-Clavulanic Acid or Dual antibiotics-Metronidazole plus one of the following-Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, Levofloxacin) will be considered acceptable. After IV abx, a regimen of oral abx will be continued for a total treatment length of 10 days. | 4 | 776 | OG000 |
| Group 2 | Appendectomy Arm | Patients in the appendectomy arm will have an appendectomy performed by an open or laparoscopic approach, depending on patient and surgeon preference. Prior to their operation, patients in this arm will receive one dose of antibiotics per currently accepted standards when appendicitis diagnosis is confirmed. Patients may also receive preoperative antibiotics per hospital standards for surgical infection prevention bundle.~Appendectomy: Appendectomy will be performed by an open or laparoscopic approach, depending on patient and surgeon preference. | 6 | 776 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Rates of Participants With Appendiceal Cancer
- Description
- Rates of appendiceal cancer among participants will be calculated among the antibiotics and appendectomy arms.
- Time frame
- Through study completion, up to 2 years
- Population
- Total number of participants is reflective of participants randomized to each arm.
Source ClinicalTrials.gov
Trial
- Title
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial
- NCT number
- NCT02800785
- Phases
- NA
- Conditions
- Appendicitis
- Interventions
- Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy
- Lead sponsor
- University of Washington
- Results first posted
- 2023-04-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02800785?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02800785-010a942b